These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 28872454)
1. Review of the Clinical Approaches to the Use of Urine-based Tumor Markers in Bladder Cancer. Clinton T; Lotan Y Rambam Maimonides Med J; 2017 Oct; 8(4):. PubMed ID: 28872454 [TBL] [Abstract][Full Text] [Related]
2. Urine markers for detection and surveillance of bladder cancer. Xylinas E; Kluth LA; Rieken M; Karakiewicz PI; Lotan Y; Shariat SF Urol Oncol; 2014 Apr; 32(3):222-9. PubMed ID: 24054865 [TBL] [Abstract][Full Text] [Related]
3. Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Lotan Y; Shariat SF; Schmitz-Dräger BJ; Sanchez-Carbayo M; Jankevicius F; Racioppi M; Minner SJ; Stöhr B; Bassi PF; Grossman HB Urol Oncol; 2010; 28(4):441-8. PubMed ID: 20610281 [TBL] [Abstract][Full Text] [Related]
4. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Tilki D; Burger M; Dalbagni G; Grossman HB; Hakenberg OW; Palou J; Reich O; Rouprêt M; Shariat SF; Zlotta AR Eur Urol; 2011 Sep; 60(3):484-92. PubMed ID: 21684071 [TBL] [Abstract][Full Text] [Related]
9. Can urinary biomarkers replace cystoscopy? Maas M; Bedke J; Stenzl A; Todenhöfer T World J Urol; 2019 Sep; 37(9):1741-1749. PubMed ID: 30283995 [TBL] [Abstract][Full Text] [Related]
10. Urinary markers in the everyday diagnosis of bladder cancer. Dal Moro F; Valotto C; Guttilla A; Zattoni F Urologia; 2013; 80(4):265-75. PubMed ID: 24419920 [TBL] [Abstract][Full Text] [Related]
11. Neural network using combined urine nuclear matrix protein-22, monocyte chemoattractant protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer. Parekattil SJ; Fisher HA; Kogan BA J Urol; 2003 Mar; 169(3):917-20. PubMed ID: 12576812 [TBL] [Abstract][Full Text] [Related]
12. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer. Kumar A; Kumar R; Gupta NP Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358 [TBL] [Abstract][Full Text] [Related]
13. Current bladder tumor tests: does their projected utility fulfill clinical necessity? Lokeshwar VB; Soloway MS J Urol; 2001 Apr; 165(4):1067-77. PubMed ID: 11257640 [TBL] [Abstract][Full Text] [Related]
14. Clinical Decision Making in Surveillance of Non-Muscle-Invasive Bladder Cancer: The Evolving Roles of Urinary Cytology and Molecular Markers. Zuiverloon TCM; de Jong FC; Theodorescu D Oncology (Williston Park); 2017 Dec; 31(12):855-62. PubMed ID: 29297169 [TBL] [Abstract][Full Text] [Related]
15. Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer. Schmitz-Dräger BJ; Todenhöfer T; van Rhijn B; Pesch B; Hudson MA; Chandra A; Ingersoll MA; Kassouf W; Palou J; Taylor J; Vlahou A; Behrens T; Critelli R; Grossman HB; Sanchez-Carbayo M; Kamat A Urol Oncol; 2014 Oct; 32(7):1061-8. PubMed ID: 24411790 [TBL] [Abstract][Full Text] [Related]
16. Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus. Schmitz-Dräger BJ; Droller M; Lokeshwar VB; Lotan Y; Hudson MA; van Rhijn BW; Marberger MJ; Fradet Y; Hemstreet GP; Malmstrom PU; Ogawa O; Karakiewicz PI; Shariat SF Urol Int; 2015; 94(1):1-24. PubMed ID: 25501325 [TBL] [Abstract][Full Text] [Related]
17. The role of fluorescence in situ hybridization assay for surveillance of non-muscle invasive bladder cancer. Karnwal A; Venegas R; Shuch B; Bassett J; Rajfer J; Reznichek R Can J Urol; 2010 Apr; 17(2):5077-81. PubMed ID: 20398445 [TBL] [Abstract][Full Text] [Related]
18. [Can the combination of bladder ultrasonography and urinary cytodiagnosis replace cystoscopy in the diagnosis and follow-up of tumors of the bladder?]. Cariou G; Maaraoui N; Cortesse A Prog Urol; 1997 Feb; 7(1):51-5. PubMed ID: 9116739 [TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors. Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic. Blick CG; Nazir SA; Mallett S; Turney BW; Onwu NN; Roberts IS; Crew JP; Cowan NC BJU Int; 2012 Jul; 110(1):84-94. PubMed ID: 22122739 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]